DE2424950A1 - Pharmazeutische allopurinol-enthaltende zubereitungen und verfahren zu ihrer herstellung - Google Patents
Pharmazeutische allopurinol-enthaltende zubereitungen und verfahren zu ihrer herstellungInfo
- Publication number
- DE2424950A1 DE2424950A1 DE19742424950 DE2424950A DE2424950A1 DE 2424950 A1 DE2424950 A1 DE 2424950A1 DE 19742424950 DE19742424950 DE 19742424950 DE 2424950 A DE2424950 A DE 2424950A DE 2424950 A1 DE2424950 A1 DE 2424950A1
- Authority
- DE
- Germany
- Prior art keywords
- allopurinol
- minutes
- tablet
- formulation according
- tablet formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims description 71
- 229960003459 allopurinol Drugs 0.000 claims description 69
- 239000002245 particle Substances 0.000 claims description 22
- 239000007916 tablet composition Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 15
- 229920003110 Primojel Polymers 0.000 claims description 11
- 239000003979 granulating agent Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000007906 compression Methods 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000008213 purified water Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 5
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 239000011812 mixed powder Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 229950002752 oxipurinol Drugs 0.000 description 4
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229910002012 Aerosil® Inorganic materials 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- -1 18 to 40 hours Chemical compound 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- XGGAWFDOIDZRPI-UHFFFAOYSA-N 4,6-Dihydroxy Natural products C1=C2OCOC2=CC(C2OC(C3C(OC(O)C32)C=2C=C3OCOC3=CC=2)O)=C1 XGGAWFDOIDZRPI-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940086845 allopurinol 100 mg Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2462873A GB1460302A (en) | 1973-05-23 | 1973-05-23 | Tablet formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2424950A1 true DE2424950A1 (de) | 1974-12-19 |
Family
ID=10214700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19742424950 Pending DE2424950A1 (de) | 1973-05-23 | 1974-05-22 | Pharmazeutische allopurinol-enthaltende zubereitungen und verfahren zu ihrer herstellung |
Country Status (21)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4143129A (en) | 1975-10-11 | 1979-03-06 | Lilly Industries Limited | Cephalexin tablets |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1533243A (en) * | 1975-02-13 | 1978-11-22 | Wellcome Found | Tablet formulation |
| US4115563A (en) * | 1977-03-14 | 1978-09-19 | Sterling Drug Inc. | Pharmaceutical steroid formulation |
| GB1601833A (en) * | 1978-02-06 | 1981-11-04 | Wellcome Found | Antacid formulation |
| DE3839825A1 (de) * | 1988-11-25 | 1990-06-13 | Henning Berlin Gmbh | Feststoffdispersionen enthaltend oxipurinol und/oder seine alkali- oder erdalkalisalze |
| EP0719547A1 (en) * | 1994-07-18 | 1996-07-03 | Luis Cipriano Carvajal Martin | Self-desintegrating compact granules used in galenic forms and containing active insoluble or hardly soluble principles |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB975850A (en) * | 1955-08-10 | 1964-11-18 | Wellcome Found | Xanthine oxidase inhibitors |
| US3624205A (en) * | 1967-04-25 | 1971-11-30 | Burroughs Wellcome Co | Treatment of hyperuricemia in humans |
-
1973
- 1973-05-23 GB GB2462873A patent/GB1460302A/en not_active Expired
-
1974
- 1974-05-22 AU AU69252/74A patent/AU469472B2/en not_active Expired
- 1974-05-22 SE SE7406864A patent/SE402525C/sv not_active IP Right Cessation
- 1974-05-22 BE BE144636A patent/BE815409A/xx not_active IP Right Cessation
- 1974-05-22 HU HUWE507A patent/HU170656B/hu unknown
- 1974-05-22 JP JP5776774A patent/JPS577128B2/ja not_active Expired
- 1974-05-22 AT AT426774A patent/AT351167B/de not_active IP Right Cessation
- 1974-05-22 ZA ZA00743318A patent/ZA743318B/xx unknown
- 1974-05-22 IE IE1097/74A patent/IE39283B1/xx unknown
- 1974-05-22 FR FR7417820A patent/FR2230341B1/fr not_active Expired
- 1974-05-22 DE DE19742424950 patent/DE2424950A1/de active Pending
- 1974-05-22 NL NLAANVRAGE7406873,A patent/NL190436C/xx not_active IP Right Cessation
- 1974-05-22 FI FI1566/74A patent/FI156674A7/fi unknown
- 1974-05-22 IL IL44877A patent/IL44877A/en unknown
- 1974-05-22 CA CA200,536A patent/CA977279A/en not_active Expired
- 1974-05-22 DK DK280174AA patent/DK144261C/da not_active IP Right Cessation
- 1974-05-23 CY CY941A patent/CY941A/xx unknown
- 1974-12-02 KE KE2808A patent/KE2808A/xx unknown
-
1978
- 1978-01-05 HK HK13/78A patent/HK1378A/xx unknown
- 1978-12-31 MY MY1978181A patent/MY7800181A/xx unknown
-
1980
- 1980-06-13 IT IT8048966A patent/IT8048966A0/it unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4143129A (en) | 1975-10-11 | 1979-03-06 | Lilly Industries Limited | Cephalexin tablets |
Also Published As
| Publication number | Publication date |
|---|---|
| CY941A (en) | 1978-06-23 |
| GB1460302A (en) | 1977-01-06 |
| AU469472B2 (en) | 1976-02-12 |
| HK1378A (en) | 1978-01-13 |
| JPS5040721A (enrdf_load_html_response) | 1975-04-14 |
| AT351167B (de) | 1979-07-10 |
| AU6925274A (en) | 1975-11-27 |
| NL190436B (nl) | 1993-10-01 |
| IE39283B1 (en) | 1978-09-13 |
| SE402525C (sv) | 1982-11-22 |
| SE402525B (sv) | 1978-07-10 |
| ATA426774A (de) | 1978-12-15 |
| HU170656B (enrdf_load_html_response) | 1977-07-28 |
| MY7800181A (en) | 1978-12-31 |
| IL44877A (en) | 1976-11-30 |
| FR2230341A1 (enrdf_load_html_response) | 1974-12-20 |
| ZA743318B (en) | 1975-05-28 |
| IL44877A0 (en) | 1974-07-31 |
| IT8048966A0 (it) | 1980-06-13 |
| IE39283L (en) | 1974-11-23 |
| NL190436C (nl) | 1994-03-01 |
| CA977279A (en) | 1975-11-04 |
| NL7406873A (enrdf_load_html_response) | 1974-11-26 |
| FR2230341B1 (enrdf_load_html_response) | 1977-04-15 |
| DK144261C (da) | 1991-02-04 |
| FI156674A7 (enrdf_load_html_response) | 1974-11-24 |
| JPS577128B2 (enrdf_load_html_response) | 1982-02-09 |
| BE815409A (fr) | 1974-11-22 |
| KE2808A (en) | 1978-02-17 |
| DK144261B (enrdf_load_html_response) | 1982-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69629755T3 (de) | Irbesartanhaltiges Arzneimittel | |
| DE68903846T2 (de) | Neue galenische form von fenofibrat. | |
| AT392901B (de) | Verfahren zur herstellung einer granulaeren form mit verzoegerter freisetzung von pharmazeutisch wirksamen substanzen | |
| DE69434479T2 (de) | Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe | |
| DE3887179T2 (de) | Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung. | |
| EP0299211B1 (de) | DHP-Manteltablette | |
| AT394310B (de) | Verfahren zur herstellung lagerstabiler, schnellzerfallender pharmazeutischer wirkstoff-presslinge | |
| EP0068191B1 (de) | Orale Dipyridamolformen | |
| EP0173210B1 (de) | Pellet-Zubereitung | |
| DE69011588T2 (de) | Pharmazeutische Formulierungen mit anhaltender Freisetzung. | |
| EP0250648B1 (de) | Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen | |
| DE69429964T2 (de) | Feste, therapeutische oder hygienische, mucoadhäsive Zusammensetzung zur Verabreichung durch Auftragen auf der Mund-schleimhaut oder der Nasen-schleimhaut | |
| DE29825080U1 (de) | Pharmazeutische Fenofibratzusammensetzung mit erhöhter Bioverfügbarkeit | |
| DE60211183T2 (de) | Pharmazeutische zusammensetzung enthaltend lumiracoxib | |
| DE4001622A1 (de) | Orale arzneimittelformen von pimobendan | |
| DE3936112C2 (de) | Arzneimittelpräparate, die Piroxicam enthalten und Verfahren zu deren Herstellung | |
| DE3100191A1 (de) | Pharmazeutische zubereitung und verfahren zu ihrer herstellung | |
| EP0146863A2 (de) | Orale retardierte Acetylsalicylsäureformulierungen | |
| DE3324209A1 (de) | Suloctidil enthaltende, oral verabfolgbare arzneimittel mit verzoegerter wirkstoffabgabe | |
| DE2424950A1 (de) | Pharmazeutische allopurinol-enthaltende zubereitungen und verfahren zu ihrer herstellung | |
| DE69728290T2 (de) | Eine wasserlösliche verbindung und cellulose enhaltende granulate | |
| DE10152351B4 (de) | Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat | |
| DE69918163T2 (de) | Ein profen enthaltende pharmazeutische mischung | |
| DE1931910A1 (de) | Verfahren zur Herstellung von festen Arzneizubereitungen mit gesteuerter Resorption | |
| CH618432A5 (en) | Process for the preparation of a 2,4-diamino-5-benzylpyrimidine intended for the production of tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHN | Withdrawal |